Journal articleJ Clin Oncol2011
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
- Journal
- J Clin Oncol
- Published
- 3 October 2011
- Citations
- 812
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 7
- BackgroundClinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer NCT05840341↗
- BackgroundThe First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients NCT05168527↗
- BackgroundA Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Pa… NCT04581343↗
- BackgroundNab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA NCT01893801↗
- BackgroundPhase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic… NCT01461915↗
- BackgroundGemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer NCT01488552↗
- BackgroundGemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer NCT00398086↗